Dr. Carlos López, group leader of the Oncological Pathology & Bioinformatics Department at the Pere Virgili Health Research Institute (Tortosa, Spain), is interested in receiving Expressions of Interest of potential candidates for the Marie Sklodowska – Curie Individual Fellowship (MSCA – IF) 2020 call.
The team has more than 15 years of experience in the study of the immune response in cancer using digital image analysis procedures applied for the quantification of tumour or immune markers. Our group have been the first to demonstrate – through paraffin-embedded samples – that the patterns of immune populations of the non-metastastic axillary lymph nodes differ between different groups of breast cancer patients. The most significant finding is that some of these differences may have clinical implications for patient outcome. The detection of the immune populations have been performed using digital image procedures.
Our research focuses in two areas:
We are looking for an experienced researcher from the field of computer sciences and machine learning, strongly committed to high quality frontier research that will be able to add new insights to the existing Groups’ core expertise in pathology and biomarker discovery. The project will utilise our database of whole slide imaging immune and tumoral markers. The main scope
is to develop image procedures that will allow us to detect image features to predict breast cancer progression.
The selected candidate will be based at the Tortosa campus, which is equipped with the technical and scientific facilities for carry out this project. In addition, the candidate will be supported by the IISPV and have access to our postgraduate training schemes.
Eligibility criteria:
At the deadline for the submission of the proposals (09/09/2020), the candidate should have:
How to apply:
Interested candidates should send a CV, motivation letter explaining your research interests, and contact details of two referees at upi@iispv.cat (E-mail Subject: “IISPV – MSCA Dr López”) by 30 April 2020.